{"id":45833,"date":"2026-07-27T20:57:00","date_gmt":"2026-07-27T18:57:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=7df42fde93143a93fc24ca7f12e6dad7"},"modified":"2026-07-27T20:57:00","modified_gmt":"2026-07-27T18:57:00","slug":"mplt-investors-have-opportunity-to-join-maplight-therapeutics-inc-fraud-investigation-with-sbs-law","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=45833","title":{"rendered":"MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law"},"content":{"rendered":"

LOS ANGELES--(BUSINESS WIRE)--$MPLT<\/a>--Schall, Brown & Schwartz<\/a> LLP (\u201cSBS\u201d), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MapLight Therapeutics, Inc. (\u201cMapLight\u201d or \u201cthe Company\u201d) (NASDAQ: MPLT<\/a>) for violations of the securities laws.<\/p><\/a><\/a>

\nINVESTIGATION DETAILS: <\/b>The investigation focuses on whether the Company issued false and\/or misleading statements and\/or failed to disclose information pertinent to investors. On July 27, 2026, MapLight shares fell more than 50% in premarket trading after its Phase 2 trial reported mixed results for its schizophrenia drug candidate. According to the Company, \u201cThe 330\/6 mg once-daily dose, which results in lower daily exposure than BID dosing, demonstrated numerical improvement over placebo, but did not achieve statistical significance on the primary endpoint, MapLight Therapeutics (MPLT) noted.\u201d Based on this news, shares of MapLight opened down 65% on the same day.<\/p>

\nIf you are a shareholder who suffered a loss, click here to participate<\/a>.<\/p>

\nWe also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com<\/a>, or by email at david@schallfirm.com<\/a><\/p>

\nWHY SBS?<\/b> Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.<\/p>

\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.<\/p> Contacts<\/b>

\nSchall, Brown & Schwartz LLP\nBrian Schall, Esq.,\nAndrew Brown, Esq.,\nDavid Schwartz, Esq.,\nwww.schallfirm.com<\/a>Office: 310-301-3335\ninfo@schallfirm.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

LOS ANGELES–(BUSINESS WIRE)–$MPLT–Schall, Brown & Schwartz LLP (\u201cSBS\u201d), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MapLight Therapeutics, Inc. (\u201cMapLight\u201d or \u201cthe Company\u201d) …<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-45833","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/45833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45833"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/45833\/revisions"}],"predecessor-version":[{"id":45834,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/45833\/revisions\/45834"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}